TRACON Pharmaceuticals Announces Results from a Clinical Trial of TRC105 in Patients with Hepatocellular Carcinoma to be Presented at the American Society of Clinical Oncology (ASCO) 2015 Gastrointestinal Cancers Symposium

San Diego, CA – January 9, 2015 – TRACON Pharmaceuticals, a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, age-related macular degeneration and fibrotic diseases, today announced that results from a clinical trial combining TRC105 with Nexavar® (sorafenib) in patients with hepatocellular carcinoma will be presented at the American Society of Clinical Oncology (ASCO) 2015 Gastrointestinal Cancers Symposium being held from January 15-17, 2015, in San Francisco.

The presentation details are as follows:

Abstract Number: 291
Abstract Title: A Phase I/II Study of TRC105 in Combination with Sorafenib in Hepatocellular Carcinoma (HCC)
Presenter: Austin G. Duffy, M.D., Center for Cancer Research, National Cancer Institute
Session: General Poster Session B
Date: Friday, January 16, 2015
Time: 12:00PM-2:00PM and 5:30PM-7:00PM

About TRC105

TRC105 is a novel, clinical stage antibody to endoglin, a protein overexpressed on proliferating endothelial cells that is essential for angiogenesis, the process of new blood vessel formation. TRC105 is currently being studied in clinical trials sponsored by both TRACON and the National Cancer Institute for the treatment of multiple solid tumor types in combination with VEGF inhibitors. TRC105 is also expected to be studied in combination with VEGF inhibitor treatments in age-related macular degeneration. For more information about the clinical trials, please visit TRACON’s website at http://www.traconpharma.com/clinical_trials.php.

About TRACON

TRACON develops targeted therapies for cancer, age-related macular degeneration and fibrotic diseases. TRACON’s current pipeline includes two clinical stage product candidates: TRC105, an anti-endoglin antibody that is being developed for the treatment of multiple solid tumor types, and TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma. Both TRC105 and TRC102 are being developed for treatment in combination with currently available
therapies. To learn more about TRACON and its product candidates, visit TRACON's website at www.traconpharma.com.

Contact:
Casey Logan
Chief Business Officer
(858) 550-0780 ext. 236
clogan@traconpharma.com